Suppr超能文献

通过微透析评估内侧前额叶皮质中多巴胺的去甲肾上腺素能来源。

Noradrenergic Source of Dopamine Assessed by Microdialysis in the Medial Prefrontal Cortex.

作者信息

Devoto Paola, Sagheddu Claudia, Santoni Michele, Flore Giovanna, Saba Pierluigi, Pistis Marco, Gessa Gian Luigi

机构信息

Section of Neuroscience and Clinical Pharmacology, Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy.

"Guy Everett" Laboratory, University of Cagliari, Cagliari, Italy.

出版信息

Front Pharmacol. 2020 Sep 23;11:588160. doi: 10.3389/fphar.2020.588160. eCollection 2020.

Abstract

Previous results indicate that dopamine (DA) release in the medial prefrontal cortex (mPFC) is modified by α adrenoceptor- but not D2 DA receptor- agonists and antagonists, suggesting that DA measured by microdialysis in the mPFC originates from noradrenergic terminals. Accordingly, noradrenergic denervation was found to prevent α-receptor-mediated rise and fall of extracellular DA induced by atipamezole and clonidine, respectively, in the mPFC. The present study was aimed to determine whether DA released by dopaminergic terminals in the mPFC is not detected by microdialysis because is readily taken up by norepinephrine transporter (NET). Accordingly, the D2-antagonist raclopride increased the electrical activity of DA neurons in the ventral tegmental area (VTA) and enhanced extracellular DOPAC but failed to modify DA in the mPFC. However, in rats whose NET was either inactivated by nisoxetine or eliminated by noradrenergic denervation, raclopride still elevated extracellular DOPAC and activated dopaminergic activity, but also increased DA. Conversely, the D2-receptor agonist quinpirole reduced DOPAC but failed to modify DA in the mPFC in control rats. However, in rats whose NET was eliminated by noradrenergic denervation or inhibited by locally perfused nisoxetine, quinpirole maintained its ability to reduce DOPAC but acquired that of reducing DA. Moreover, raclopride and quinpirole, when locally perfused into the mPFC of rats subjected to noradrenergic denervation, were able to increase and decrease, respectively, extracellular DA levels, while being ineffective in control rats. Transient inactivation of noradrenergic neurons by clonidine infusion into the locus coeruleus, a condition where NET is preserved, was found to reduce extracellular NE and DA in the mPFC, whereas noradrenergic denervation, a condition where NET is eliminated, almost totally depleted extracellular NE but increased DA. Both transient inactivation and denervation of noradrenergic neurons were found to reduce the number of spontaneously active DA neurons and their bursting activity in the VTA. The results indicate that DA released in the mPFC by dopaminergic terminals is not detected by microdialysis unless DA clearance from extracellular space is inactivated. They support the hypothesis that noradrenergic terminals are the main source of DA measured by microdialysis in the mPFC during physiologically relevant activities.

摘要

先前的研究结果表明,内侧前额叶皮质(mPFC)中的多巴胺(DA)释放可被α肾上腺素能受体激动剂和拮抗剂改变,但不受D2多巴胺受体激动剂和拮抗剂的影响,这表明通过微透析测量的mPFC中的DA源自去甲肾上腺素能终末。因此,发现去甲肾上腺素能去神经支配可分别阻止阿替美唑和可乐定诱导的mPFC中细胞外DA的α受体介导的升高和降低。本研究旨在确定mPFC中多巴胺能终末释放的DA是否未被微透析检测到,因为它很容易被去甲肾上腺素转运体(NET)摄取。因此,D2拮抗剂雷氯必利增加了腹侧被盖区(VTA)中DA神经元的电活动并增强了细胞外3,4-二羟基苯乙酸(DOPAC),但未能改变mPFC中的DA。然而,在NET被尼索西汀灭活或被去甲肾上腺素能去神经支配消除的大鼠中,雷氯必利仍然升高细胞外DOPAC并激活多巴胺能活性,同时也增加了DA。相反,D2受体激动剂喹吡罗降低了DOPAC,但在对照大鼠中未能改变mPFC中的DA。然而,在NET被去甲肾上腺素能去神经支配消除或被局部灌注的尼索西汀抑制的大鼠中,喹吡罗保持其降低DOPAC的能力,但获得了降低DA的能力。此外,雷氯必利和喹吡罗在局部灌注到去甲肾上腺素能去神经支配的大鼠的mPFC中时,能够分别增加和降低细胞外DA水平,而在对照大鼠中则无效。发现通过向蓝斑核注入可乐定使去甲肾上腺素能神经元短暂失活(NET保持完整的情况)可降低mPFC中的细胞外去甲肾上腺素(NE)和DA,而去甲肾上腺素能去神经支配(NET被消除的情况)几乎完全耗尽细胞外NE但增加了DA。发现去甲肾上腺素能神经元的短暂失活和去神经支配均会减少VTA中自发活动的DA神经元数量及其爆发活动。结果表明,除非细胞外空间的DA清除被灭活,否则多巴胺能终末在mPFC中释放的DA不会被微透析检测到。这些结果支持以下假设:在生理相关活动期间,去甲肾上腺素能终末是通过微透析测量的mPFC中DA的主要来源。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e214/7538903/c95aa82b8c02/fphar-11-588160-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验